$420 Million is the total value of Sio Capital Management, LLC's 69 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ITCI | New | INTRA-CELLULAR THERAPIES INCput | $66,795,000 | – | 1,946,800 | +100.0% | 15.91% | – |
| MRK | New | MERCK & CO INC | $15,439,000 | – | 169,755 | +100.0% | 3.68% | – |
| GILD | New | GILEAD SCIENCES INC | $12,086,000 | – | 186,000 | +100.0% | 2.88% | – |
| GSK | New | GLAXOSMITHKLINE PLCsponsored adr | $9,619,000 | – | 204,705 | +100.0% | 2.29% | – |
| SNY | New | SANOFI SAsponsored adr | $8,583,000 | – | 170,977 | +100.0% | 2.04% | – |
| IMVT | New | IMMUNOVANT INC*w exp 12/18/2024 | $5,483,000 | – | 615,400 | +100.0% | 1.31% | – |
| MMSI | New | MERIT MEDICAL SYSTEMS INC | $4,683,000 | – | 150,000 | +100.0% | 1.12% | – |
| ARDX | New | ARDELYX INC | $4,665,000 | – | 621,534 | +100.0% | 1.11% | – |
| ESPR | New | ESPERION THERAPEUTICS INC | $3,379,000 | – | 56,658 | +100.0% | 0.80% | – |
| SYRS | New | SYROS PHARMACEUTICALS INC | $3,099,000 | – | 448,532 | +100.0% | 0.74% | – |
| SAGE | New | SAGE THERAPEUTICS INCput | $3,025,000 | – | 41,900 | +100.0% | 0.72% | – |
| New | TRILLIUM THERAPEUTICS INC | $2,834,000 | – | 2,751,186 | +100.0% | 0.68% | – | |
| AFMD | New | AFFIMED NV | $2,790,000 | – | 1,018,200 | +100.0% | 0.66% | – |
| ZFGN | New | ZAFGEN INC | $2,534,000 | – | 2,283,164 | +100.0% | 0.60% | – |
| ASLN | New | ASLAN PHARMACEUTICALS LTDads | $2,066,000 | – | 1,017,971 | +100.0% | 0.49% | – |
| RDUS | New | RADIUS HEALTH INC | $2,016,000 | – | 100,000 | +100.0% | 0.48% | – |
| WVE | New | WAVE LIFE SCIENCES LTDcall | $1,756,000 | – | 219,100 | +100.0% | 0.42% | – |
| PHG | New | KONINKLIJKE PHILIPS NVput | $1,649,000 | – | 33,800 | +100.0% | 0.39% | – |
| ARAV | New | ARAVIVE INC | $1,342,000 | – | 98,201 | +100.0% | 0.32% | – |
| BCEL | New | ATRECA INC | $1,320,000 | – | 85,312 | +100.0% | 0.31% | – |
| BEAT | New | BIOTELEMETRY INCput | $1,306,000 | – | 28,200 | +100.0% | 0.31% | – |
| PGNY | New | PROGYNY INC | $1,233,000 | – | 44,910 | +100.0% | 0.29% | – |
| ARVN | New | ARVINAS INC | $1,235,000 | – | 30,052 | +100.0% | 0.29% | – |
| OPK | New | OPKO HEALTH INC | $1,184,000 | – | 805,311 | +100.0% | 0.28% | – |
| OVID | New | OVID THERAPEUTICS INC | $1,098,000 | – | 264,581 | +100.0% | 0.26% | – |
| NLTX | New | NEOLEUKIN THERAPEUTICS INC | $1,086,000 | – | 88,185 | +100.0% | 0.26% | – |
| MRSN | New | MERSANA THERAPEUTICS INC | $953,000 | – | 166,250 | +100.0% | 0.23% | – |
| ABEO | New | ABEONA THERAPEUTICS INC | $924,000 | – | 282,520 | +100.0% | 0.22% | – |
| KRTX | New | KARUNA THERAPEUTICS INC | $722,000 | – | 9,588 | +100.0% | 0.17% | – |
| DTIL | New | PRECISION BIOSCIENCES INC | $603,000 | – | 43,433 | +100.0% | 0.14% | – |
| LPTX | New | LEAP THERAPEUTICS INC | $533,000 | – | 476,223 | +100.0% | 0.13% | – |
| CMD | New | CANTEL MEDICAL CORPput | $518,000 | – | 7,300 | +100.0% | 0.12% | – |
| MTD | New | METTLER-TOLEDO INTERNATIONAL INCput | $317,000 | – | 400 | +100.0% | 0.08% | – |
| New | APTOSE BIOSCIENCES INC | $284,000 | – | 50,000 | +100.0% | 0.07% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VIKING THERAPEUTICS INC | 24 | Q3 2023 | 3.4% |
| UNITED THERAPEUTICS ORD | 23 | Q3 2023 | 8.3% |
| CARDINAL HEALTH ORD | 20 | Q2 2022 | 7.2% |
| SANOFI SA | 19 | Q3 2022 | 9.8% |
| MEDTRONIC PLC | 18 | Q3 2023 | 5.2% |
| CATALYST BIOSCIENCES INC | 18 | Q3 2021 | 17.8% |
| PFENEX ORD | 18 | Q4 2019 | 5.9% |
| AEGLEA BIOTHERAPEUTICS INC | 18 | Q1 2023 | 1.1% |
| HCA HEALTHCARE INC | 17 | Q2 2022 | 5.5% |
| MCKESSON ORD | 17 | Q1 2022 | 6.0% |
View Sio Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Modular Medical, Inc. | February 13, 2023 | 1,091,479 | 10.0% |
| Cellectar Biosciences, Inc. | February 10, 2022 | ? | ? |
| CURIS INC | February 10, 2022 | 3,866,645 | 4.2% |
| Salarius Pharmaceuticals, Inc. | February 10, 2022 | 1,354,291 | 3.0% |
| Larimar Therapeutics, Inc. | February 16, 2021 | 188,661 | 1.2% |
| ACHIEVE LIFE SCIENCES, INC. | February 14, 2020 | ? | ? |
| Bionano Genomics, Inc | February 14, 2020 | 1,210,821 | 4.6% |
| Brickell Biotech, Inc. | February 14, 2020 | ? | ? |
| Trillium Therapeutics Inc. | February 14, 2020 | 2,751,186 | 9.8% |
| ZAFGEN, INC. | February 14, 2020 | 2,283,164 | 6.1% |
View Sio Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13G | 2023-02-13 |
View Sio Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.